Muscle-derived cell mediated gene delivery for treating muscle-and bone-related injury or dysfunction
CA 2330660 C · Owner: Chancellor, Michael B. · Inventors: Chancellor, Michael B.; Huard, Johnny
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides muscle-derived cells preferably myoblasts and , muscle-derived stem cells genetically engineered to contain and express one or more heterologous genes or functional segments of such genes for delivery , of the encoded gene products at or near sites of musculoskeletal bone, ligament, meniscus, cartilage or genitourinary disease injury, defect, or , dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 30, 1999 and granted April 10, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 30, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 30, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.